Service de Neuro-urology, hôpital Tenon
Paris, 75020, France
NCT Number: NCT03204747
Multiple sclerosis causes demyelinating lesions, which can induce multiple symptoms. If motor disorders are the most visible disability, urinary disorders are frequent, with prevalence from 32 to 86%. The first ones are due to pyramidal, cerebellar or proprioceptive lesions. The seconds are due to specific lesion in inhibitor/activator encephalic centers, or interruption on medullary conduction. It seems to be evident that walk and urinary disorders are link, because of similar anatomic ways and control process. Effect of bladder filling is well known on motoneuronal excitability. The effect of bladder filling on walk stay unknown, while medullary integration of these two functions is very close, in medullary cone.
Primary aim is to assess the effect of need to void on walk speed in multiple sclerosis with lower urinary tract symptoms. Secondary aim is to identify clinical or urodynamic factor link with major walk impairment when patients need to void.
Patient with multiple sclerosis over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
History and treatment, high, weigh, symptoms severity by USP score, cognitive impairment by MMSE score and last urodynamic data are recorded. Patient are asked to drink water until they feel a strong need to void, for which they would go to urinate at home.
Walk tests are realized in a specific place, with calm and no passage. A chair is placed at each end of the path. Toilets are just next to the hall where they realize the tests. A 10 Meters Walk Test is done during this condition, 3 times (only the intermediate 6 meters are recorded). They can take 30 seconds of rest between each try if necessary. One Timed up and go is done. Patient can use their habitual walking device. Speed walk asking is comfortable for the two test.
Next, patient can urinate. 3 post void residual volume with portable echography are done, and the higher is recorded.
Patient achieve the same walk tests after urinate, in the same order. They must use the same walking device.
Primary outcome is mean gait recorded for 10 meters walk test.
Secondary outcome is time for timed up and go test.
Individual variability between the 3 10MWT in the two conditions will be study.
Influence of age, EDSS, severity of symptoms, MMSE, detrusor overactivity on speed impairment will be study in secondary analysis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Paris, 75020, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention, only propose water and wait for need to void
Time frame: 1 Day: at strong desire to void and just after void
Gait speed calculated from 10 meter walk test. Only the 6 intermediate meters are recorded. Time is recorded by a manual chronometer. 3 records are done, mean time is calculated. Mean time is divided by 6 to obtain mean gait speed
Time frame: 1 Day: at strong desire to void and just after void
1 record is done for timed up and go test after a first training. Time is recorded by a manual chronometer
Time frame: 1 Day: for strong desire to void and post void
Coefficient of variation is calculated from the 3 records of 10 meter walk test. It correspond to standard deviation/average.
Pierre and Marie Curie University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03033355
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Houston, Texas, United States
View Trial DetailsNCT04063852
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ann Arbor, Michigan, United States
View Trial DetailsNCT04338646
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsNCT04528784
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Limerick, LK, Ireland
View Trial Details